Benjamin Bonavida
Impact in
- Immunology top 0.2%
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Oncology top 0.2%
- CAR-T cell therapy research
Papers in
- Immunology 209
- Immune Cell Function and Interaction 102
- Immunotherapy and Immune Responses 63
- T-cell and B-cell Immunology 44
-
- Cell death mechanisms and regulation 55
- Melanoma and MAPK Pathways 30
- Co-authors
- Ali R. Jazirehi (36 shared papers)Hermes Garbán (22 shared papers)Steve Alas (6 shared papers)Sara Huerta‐Yépez (62 shared papers)Stavroula Baritaki (46 shared papers)Samantha Kaufhold (8 shared papers)Mario I. Vega (51 shared papers)Susan C. Wright (12 shared papers)
- Journals
- Blood (56 papers)The Journal of Immunology (49 papers)International Journal of Oncology (18 papers)Critical Reviews™ in Oncogenesis (17 papers)Cellular Immunology (15 papers)
- Partner nations
- United StatesMexicoJapan
In The Last Decade
Benjamin Bonavida
456 papers receiving 16.0k citations
Benjamin Bonavida's Hit Papers
Peers
Comparison fields: 5 of 147
- Immunology 5.3k
- Oncology 4.0k
- Cancer Research 2.1k
- Pathology and Forensic Medicine 2.2k
- Virology 498
Countries citing papers authored by Benjamin Bonavida
This map shows the geographic impact of Benjamin Bonavida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Bonavida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Bonavida more than expected).
Fields of papers citing papers by Benjamin Bonavida
This network shows the impact of papers produced by Benjamin Bonavida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Bonavida. The network helps show where Benjamin Bonavida may publish in the future.
Co-authors
The 25 scholars most cited alongside Benjamin Bonavida, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 470 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Transcription factor YY1: structure, function, and therapeutic implications in cancer biology Hit paper breakdown → | 2005 | 605 |
| 2 | 2014 | 358 | |
| 3 | 1997 | 328 | |
| 4 | 2014 | 289 | |
| 5 | Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. | 2001 | 244 |
| 6 | Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. | 2001 | 231 |
| 7 | 2012 | 219 | |
| 8 | 2005 | 206 | |
| 9 | Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. | 2003 | 198 |
| 10 | 1995 | 188 | |
| 11 | Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. | 1979 | 185 |
| 12 | 1988 | 166 | |
| 13 | 2007 | 163 | |
| 14 | 2004 | 157 | |
| 15 | 2004 | 152 | |
| 16 | 1979 | 152 | |
| 17 | Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. | 1995 | 148 |
| 18 | Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. | 2005 | 143 |
| 19 | 2005 | 140 | |
| 20 | 1986 | 133 |
About Benjamin Bonavida
Benjamin Bonavida is a scholar working on Immunology, Molecular Biology, Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 470 papers that have together received 16.6k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (102 papers), Immunotherapy and Immune Responses (63 papers), Monoclonal and Polyclonal Antibodies Research (57 papers), Cell death mechanisms and regulation (55 papers), T-cell and B-cell Immunology (44 papers), NF-κB Signaling Pathways (33 papers), Melanoma and MAPK Pathways (30 papers) and Multiple Myeloma Research and Treatments (29 papers). The work is most often cited by research in Immunology (5.3k citations), Oncology (4.0k citations), Cancer Research (2.1k citations), Pathology and Forensic Medicine (2.2k citations) and Virology (498 citations). Benjamin Bonavida has collaborated with scholars based in United States, Mexico and Japan. Frequent co-authors include Ali R. Jazirehi, Hermes Garbán, Steve Alas, Sara Huerta‐Yépez, Stavroula Baritaki, Samantha Kaufhold, Mario I. Vega, Susan C. Wright, Anahid Jewett and Elizabeth A. Grimm. Their work appears in journals such as Blood, The Journal of Immunology, International Journal of Oncology, Critical Reviews™ in Oncogenesis and Cellular Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.